Looking at the future of neurodegeneration research!

The rare complication known as multisystem inflammatory syndrome in children (MIS-C) differs from both Kawasaki disease and severe adult cases of COVID-19, a study finds.

A meta-analysis of seven randomized controlled trials concludes that dexamethasone and other corticosteroids reduce 28-day mortality in seriously ill patients.

A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.

The presence of a particular set of RNAs in the blood forewarns of an onset of severe symptoms and points to the cells involved.

The cholesterol-lowering drugs quell inflammation and reverse endothelial tissue damage, hints that they might curb the body’s excessive immune response to SARS-CoV-2 infection.

Drugs targeting patients’ immune systems, rather than the virus itself, could be key to recovery from severe cases of the disease, some researchers suggest.

By studying influenza in mice and cells, researchers identify a glucose metabolism pathway critical to the dysregulated immune response that kills many infectious disease patients, including those with COVID-19.

The symptoms suggest SARS-CoV-2 might infect neurons, raising questions about whether there could be effects on the brain that play a role in patients’ deaths, but the data are preliminary.